Indaptus Therapeutics (NASDAQ:INDP) Announces Quarterly Earnings Results

Indaptus Therapeutics (NASDAQ:INDP) released its earnings results on Thursday. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.03, Zacks reports.

Indaptus Therapeutics Stock Up 0.4 %

INDP traded up $0.00 on Friday, reaching $0.81. 2,761 shares of the company traded hands, compared to its average volume of 45,358. The company has a market cap of $11.44 million, a P/E ratio of -0.47 and a beta of 1.60. Indaptus Therapeutics has a one year low of $0.70 and a one year high of $3.10. The firm has a fifty day simple moving average of $0.86 and a two-hundred day simple moving average of $1.09.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.